10-KPeriod: FY2024

Medtronic plc Annual Report, Year Ended Apr 26, 2024

Filed June 20, 2024For Securities:MDT

Summary

Medtronic plc reported solid performance in its fiscal year 2024, with total net sales increasing by 4% to $32.36 billion. The company's growth was driven by its Neuroscience Portfolio (up 5%), Medical Surgical Portfolio (up 5%), and particularly its Diabetes Operating Unit (up 10%). Key product areas showing strength include Cardiac Rhythm & Heart Failure, Coronary & Peripheral Vascular, Cranial & Spinal Technologies, and Surgical & Endoscopy divisions. Financially, Medtronic demonstrated strong operating cash flow and free cash flow, with free cash flow reaching $5.2 billion. The company also returned value to shareholders through dividends and share repurchases, authorizing an additional $5.0 billion for repurchases. Despite global economic uncertainties and some product-specific challenges, Medtronic's diversified business segments and international presence contributed to resilient growth. The company continues to invest in innovation, with R&D expenses remaining consistent year-over-year.

Financial Highlights

56 data points
Beta

Revenue

$32.36B

65.3% Gross Margin

Net Income

$3.71B

11.4% Net Margin

EPS (Diluted)

$2.76

Total Assets

$89.98B

Cash & Equivalents

$1.28B

Free Cash Flow

$5.20B

Financial Statements
Beta
Revenue$32.36B
Cost of Revenue$11.22B
Gross Profit$21.15B
SG&A Expenses$10.74B
Operating Income$5.14B
Interest Expense$719.00M
Net Income$3.71B
EPS (Basic)$2.77
EPS (Diluted)$2.76
Shares Outstanding (Basic)1.33B
Shares Outstanding (Diluted)1.33B

Key Highlights

  • 1Total net sales increased by 4% to $32.36 billion for fiscal year 2024.
  • 2Neuroscience, Medical Surgical, and Diabetes segments showed robust growth of 5%, 5%, and 10% respectively.
  • 3Free cash flow was strong at $5.2 billion, indicating healthy operational performance and cash generation.
  • 4Medtronic authorized an additional $5.0 billion for share repurchases, demonstrating commitment to shareholder returns.
  • 5Key product launches and adoption of new technologies, such as the PulseSelect PFA system and the Aurora EV-ICD system, are driving growth in the Cardiovascular segment.
  • 6The company is strategically exiting certain product lines, such as ventilators, to focus resources on core growth areas.
  • 7R&D expenses remained stable at $2.7 billion, underscoring continued investment in innovation across its portfolios.

Frequently Asked Questions

Medtronic reported a 4% increase in total net sales, reaching $32.36 billion for fiscal year 2024. The company demonstrated strong free cash flow of $5.2 billion and continued to return value to shareholders through dividends and share repurchases. Growth was observed across most business segments, with notable strength in Neuroscience, Medical Surgical, and Diabetes.

The Diabetes Operating Unit showed the strongest growth at 10%. The Neuroscience Portfolio and Medical Surgical Portfolio also performed well, with 5% growth each. Within the Cardiovascular Portfolio, Cardiac Rhythm & Heart Failure and Coronary & Peripheral Vascular segments grew by 4%.

Medtronic remains committed to innovation, maintaining R&D expenses at $2.7 billion. The company is focusing on leveraging its pipeline to accelerate revenue growth, creating and disrupting markets with technology, and utilizing AI and data analytics. Specific growth drivers highlighted include new product introductions and market adoption in areas like pulsed field ablation (PFA) and extravascular ICDs.

Medtronic generated strong free cash flow and demonstrated its commitment to shareholder returns by authorizing an additional $5.0 billion for share repurchases. The company also announced an increase in its quarterly cash dividend. This financial flexibility allows for continued investment in R&D and strategic acquisitions.